VantAI

VantAI is an AI application focused on generative AI-enabled drug discovery. Their mission is to unlock a new chapter in medicine by making protein interactions programmable. They have an integrated discovery platform with phase-shifting technologies designed to unlock the full potential of the proximity modulator modality. VantAI collaborates with industry leaders to build the future of therapeutic design. The company has launched Neo-1, the first AI model to rewire molecular interactions by unifying structure prediction and generation.

Genesis Molecular AI is a pioneering molecular AI platform that builds and deploys GEMS, the AI Operating System for drug discovery. Their platform, including the model Pearl, empowers scientists to unlock tough protein targets and invent medicines with unprecedented potency and selectivity. Genesis combines AI and physics research to create a state-of-the-art platform for drug discovery, providing highly potent and selective drugs to address chemically complex targets. The company's success is attributed to a collaborative mix of minds across AI and biotech, working in iterative, interdisciplinary loops to discover and develop drugs for challenging targets.

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery blending science and technology with a focus on finding solutions for complex diseases. We empower both biopharmaceutical companies and our internal scientists to harness the full potential of data and AI to accelerate the next generation of scientific advances. We have built our AI-enabled drug discovery engine to drive a revolution in drug discovery. The Benevolent Platform™ unlocks the power of a vast biomedical data landscape to provide a multidimensional representation of human biology across all diseases. We believe this approach will improve the probability of clinical success, and help us deliver life-changing treatments to patients – because it matters.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

neurons.bio is an AI application that offers a unique collection of over 100 AI agents designed for drug development, medicine, and life science research. These agents perform specific tasks efficiently, retrieve data from various sources, and provide insights to accelerate research processes. The platform aims to revolutionize drug discovery and development by integrating cutting-edge LLM technology with domain-specific agents, reducing research costs and time to clinic.

Kuano is an AI tool that focuses on redefining drug discovery using Quantum and AI technologies. The platform offers world-class scientific expertise in quantum physics, AI, and medicinal chemistry to revolutionize the drug design process. Kuano aims to leverage cutting-edge technologies to accelerate the discovery of new drugs and improve healthcare outcomes.

Exscientia is a technology-driven drug design and development company that combines precision design with integrated experimentation to create more effective medicines for patients faster. They operate at the interfaces of human ingenuity, artificial intelligence (AI), automation, and physical engineering, pioneering the use of AI in drug discovery. Exscientia aims to change the underlying economics of drug discovery by rapidly advancing the best scientific ideas into medicines for patients.

QuantNexus is an applied research collective that pioneers the future of molecular discovery through intelligent automation. Their mission is to empower the next generation of scientists by creating a human and AI partnership that advances biology significantly. The platform, NovoQuantNexus, fuses machine intelligence with human creativity to achieve breakthroughs in record time, outpacing conventional methods and pure-AI approaches. Researchers in pharma, biotech, and academia are leveraging this technology to accelerate discovery and redefine possibilities in life sciences.

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Deep Genomics is a company that uses artificial intelligence (AI) to develop RNA therapies for genetic diseases. The company's AI platform is designed to identify novel targets and evaluate thousands of possibilities to identify the best therapeutic candidates. Deep Genomics is currently developing BigRNA+, which will expand the number of mechanisms and genetic variants the company can pursue.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Allchemy is a resource-aware AI platform for drug discovery. It combines state-of-the-art computational synthesis with AI algorithms to predict molecular properties. Within minutes, Allchemy creates thousands of synthesizable lead candidates meeting user-defined profiles of drug-likeness, affinity towards specific proteins, toxicity, and a range of other physical-chemical measures. Allchemy encompasses the entire resource-to-drug design process and has been used in academic, corporate and classified environments worldwide to: Design synthesizable leads targeting specific proteins Evolve scaffolds similar to desired drugs Design “circular” drug syntheses from renewable materials Interface with and instruct automated synthesis platforms and optimize pilot-scale processes Operate “iterative synthesis” schemes Predict side reactions and create forensic “synthetic signatures” of hazardous/toxic molecules Design synthetic degradation and recovery cycles for various types of feedstocks and functional target molecules

Lavo Life Sciences is an AI-accelerated crystal structure prediction application that helps in drug development by providing accurate predictions for small molecule drugs. The application utilizes AI technology to optimize solid-state formulations, reduce turnaround time, mitigate risks, and discover novel polymorphs, ultimately streamlining the pharmaceutical research and development process.

Moonvalley is a research company focused on developing generative media using deep learning technology. The team consists of experienced researchers, engineers, and artists from renowned companies such as Deepmind, IBM, and Microsoft. Moonvalley aims to revolutionize the field of generative video production through cutting-edge AI techniques.

Moonvalley is a research company focused on developing cutting-edge generative media technologies. The team consists of top researchers, engineers, and artists with backgrounds in leading tech companies. Moonvalley specializes in advanced video and image machine learning models, aiming to shape the future of media creation.

The DARPA's Artificial Intelligence Cyber Challenge (AIxCC) is an AI-driven cybersecurity tool developed in collaboration with ARPA-H and various industry experts like Anthropic, Google, Microsoft, OpenAI, and others. It aims to safeguard critical software infrastructure by utilizing AI technology to enhance cybersecurity measures. The tool provides a platform for experts in AI and cybersecurity to come together and address the evolving threats in the digital landscape.

VantAI is an AI application focused on generative AI-enabled drug discovery. Their mission is to unlock a new chapter in medicine by making protein interactions programmable. They have an integrated discovery platform with phase-shifting technologies designed to unlock the full potential of the proximity modulator modality. VantAI collaborates with industry leaders to build the future of therapeutic design. The company has launched Neo-1, the first AI model to rewire molecular interactions by unifying structure prediction and generation.

Genesis Molecular AI is a pioneering molecular AI platform that builds and deploys GEMS, the AI Operating System for drug discovery. Their platform, including the model Pearl, empowers scientists to unlock tough protein targets and invent medicines with unprecedented potency and selectivity. Genesis combines AI and physics research to create a state-of-the-art platform for drug discovery, providing highly potent and selective drugs to address chemically complex targets. The company's success is attributed to a collaborative mix of minds across AI and biotech, working in iterative, interdisciplinary loops to discover and develop drugs for challenging targets.

Synthace is a software and expertise platform designed for Discovery Biology Teams to streamline and optimize their experiments in assay development, media optimization, and purification process development. The platform offers software solutions, training, and on-site support from specialists to help scientists conduct experiments more efficiently and effectively. By leveraging multifactorial methods and automation, Synthace aims to accelerate drug discovery processes and deliver faster, definitive results.

HUAWEI Cloud Pangu is an AI tool designed for accelerating drug discovery by optimizing drug molecules. It offers features such as Molecule Search, Molecule Optimizer, and Pocket Molecule Design. Users can submit molecules for optimization and view historical optimization results. The tool is based on the MindSpore framework and has been visited over 300,000 times since August 23, 2021.

VantAI is an AI application focused on generative AI-enabled drug discovery. Their mission is to unlock a new chapter in medicine by making protein interactions programmable. They have an integrated discovery platform with phase-shifting technologies designed to unlock the full potential of the proximity modulator modality. VantAI collaborates with industry leaders to build the future of therapeutic design. The company has launched Neo-1, the first AI model to rewire molecular interactions by unifying structure prediction and generation.

Mind-Video is an AI tool that focuses on high-quality video reconstruction from brain activity data. It bridges the gap between image and video brain decoding by utilizing masked brain modeling, multimodal contrastive learning, spatiotemporal attention, and co-training with an augmented Stable Diffusion model. The tool aims to recover accurate semantic information from fMRI signals, enabling the generation of realistic videos based on brain activities.

Boff.ai is an AI tool that connects professionals with academia to unlock opportunities and funding for research and development teams. It helps users ask specific questions across various topics and sources replies from experts in the field. The platform ensures privacy and focuses on solutions required, making it a trusted resource for 30,000 academics and R&D professionals.

Modality.AI is an AI application that has developed an automated, clinically validated system to assess neurological and psychiatric states both in clinic and remotely. The platform utilizes conversational AI to monitor conditions accurately and consistently, allowing researchers and clinicians to review data in near real-time and monitor treatment response over time. Modality.AI collaborates with world-class AI/Machine Learning experts and leading institutions to provide a HIPAA-compliant system for assessing various indications such as ALS, Parkinson's, depression, autism, Huntington's Disease, schizophrenia, and mild cognitive impairment. The platform enables convenient monitoring at home through streaming and analysis of speech and facial responses, without the need for special software or apps. Modality.AI is accessible on various devices with a browser, webcam, and microphone, offering a new approach to efficient and cost-effective clinical trials.

Neuralink is a pioneering brain-computer interface (BCI) application that aims to redefine human capabilities by creating a generalized brain interface to restore autonomy to individuals with unmet medical needs. The application focuses on developing fully implantable BCIs that allow users, particularly those with quadriplegia, to control computers and mobile devices using their thoughts. Neuralink's innovative technology includes advanced chips, biocompatible enclosures, and surgical robots for precise implantation. The application prioritizes safety, accessibility, and reliability in its engineering process, with future goals of restoring vision, motor function, and speech capabilities.

Ascenscia is a specialized AI voice assistant designed to streamline lab digitization processes. It integrates with laboratory software and machines to enable hands-free interactions, automating data collection, optimizing workflows, and accelerating R&D cycles. Ascenscia offers features such as data accessibility, data capturing, inventory access, and additional task management. The application is designed for scientific labs, addressing concerns with precision, safety, and adaptability. It boasts high accuracy in understanding scientific terminologies, end-to-end data encryption, multi-lingual support, and customization options for different lab workflows.

Nucleai is an AI-driven spatial biomarker analysis tool that leverages military intelligence-grade geospatial AI methods to analyze complex cellular interactions in a patient's biopsy. The platform offers a first-of-its-kind multimodal solution by ingesting images from various modalities and delivering actionable insights to optimize biomarker scoring, predict response to therapy, and revolutionize disease diagnosis and treatment.

Exscientia is a technology-driven drug design and development company that combines precision design with integrated experimentation to create more effective medicines for patients faster. They operate at the interfaces of human ingenuity, artificial intelligence (AI), automation, and physical engineering, pioneering the use of AI in drug discovery. Exscientia aims to change the underlying economics of drug discovery by rapidly advancing the best scientific ideas into medicines for patients.

Paige is a leading AI company revolutionizing pathology with next-generation technology. They provide diagnostic and biomarker AI, predictive analytics technology, and AI-assisted applications to support cancer detection, subtyping, and molecular biomarker discovery from tissue samples. Paige offers a range of AI suites for prostate, breast, colon, and PanCancer, as well as the innovative Paige Alba™ multi-modal co-pilot. Their advanced AI technology and services help streamline AI development, optimize existing applications, and drive groundbreaking advancements in cancer care.

Undermind is an AI-powered scientific research assistant that revolutionizes the way researchers access and analyze academic papers. By utilizing intelligent language models, Undermind reads and synthesizes information from hundreds of papers to provide accurate and comprehensive results. Researchers can describe their queries in natural language, and Undermind assists in finding relevant papers, brainstorming questions, and discovering crucial insights. Trusted by researchers across various fields, Undermind offers a unique approach to literature search, surpassing traditional search engines in accuracy and efficiency.

Salt AI is a development engine tailored for life sciences organizations, aiming to accelerate advancements in the field by enabling faster adoption and utilization of AI technologies. The platform offers reliable and reproducible AI processes, optimized for speed and efficiency, and promotes transparency and collaboration within workflows. With a focus on supporting best-in-class life sciences research models, Salt AI empowers users to enhance their understanding of biological processes through flexible and performant AI solutions.

QuantNexus is an applied research collective that pioneers the future of molecular discovery through intelligent automation. Their mission is to empower the next generation of scientists by creating a human and AI partnership that advances biology significantly. The platform, NovoQuantNexus, fuses machine intelligence with human creativity to achieve breakthroughs in record time, outpacing conventional methods and pure-AI approaches. Researchers in pharma, biotech, and academia are leveraging this technology to accelerate discovery and redefine possibilities in life sciences.

PhysioNet is a research resource for complex physiologic signals that facilitates finding, sharing, and reusing health data. It provides access to various datasets and software tools for researchers in the medical field. PhysioNet aims to support the responsible use of data, including guidelines for creating datasets and models from sources like MIMIC. The platform also addresses access restrictions under the DOJ Data Security Program, ensuring compliance with legal obligations while supporting researchers in understanding and navigating policy changes.

Kriv AI is an advanced AI tool designed for the healthcare and life sciences industries. It offers cutting-edge technology to assist professionals in making informed decisions and improving patient outcomes. By leveraging Governed Agentic AI, Kriv AI provides a reliable and efficient solution for complex challenges in the medical field.

Cradle is a protein engineering platform that uses machine learning to design improved protein sequences. It allows users to import assay data, generate new sequences, test them in the lab, and import the results to improve the model. Cradle can be used to optimize multiple properties of a protein simultaneously, and it has been used by leading biotech teams to accelerate new and ongoing projects.

Owkin is a full-stack AI biotech company that integrates the best of human and artificial intelligence to deliver better drugs and diagnostics at scale. By understanding complex biology through AI, Owkin identifies new treatments, de-risks and accelerates clinical trials, and builds diagnostic tools to reduce time to impact for patients.

Cerebras is an AI tool that offers products and services related to AI supercomputers, cloud system processors, and applications for various industries. It provides high-performance computing solutions, including large language models, and caters to sectors such as health, energy, government, scientific computing, and financial services. Cerebras specializes in AI model services, offering state-of-the-art models and training services for tasks like multi-lingual chatbots and DNA sequence prediction. The platform also features the Cerebras Model Zoo, an open-source repository of AI models for developers and researchers.

CCDS (Center for Computational & Data Sciences) is a research center at Independent University Bangladesh dedicated to artificial intelligence, data sciences, and computational science. The center has various wings focusing on AI, computational biology, physics, data science, human-computer interaction, and industry partnerships. CCDS explores the use of computation to understand nature and society, uncover hidden stories in data, and tackle complex challenges. The center collaborates with institutions like CERN and the Dunlap Institute for Astronomy and Astrophysics.

Variational AI is a company that uses generative AI to discover novel drug-like small molecules with optimized properties for defined targets. Their platform, Enki™, is the first commercially accessible foundation model for small molecules. It is designed to make generating novel molecule structures easy, with no data required. Users simply define their target product profile (TPP) and Enki does the rest. Enki is an ensemble of generative algorithms trained on decades worth of experimental data with proven results. The company was founded in September 2019 and is based in Vancouver, BC, Canada.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

XtalPi is a world-leading technology company driven by artificial intelligence (AI) and robotics to innovate in the fields of life sciences and new materials. Founded in 2015 at the Massachusetts Institute of Technology (MIT), the company is committed to realizing digital and intelligent innovation in the fields of life sciences and new materials. Based on cutting-edge technologies and capabilities such as quantum physics, artificial intelligence, cloud computing, and large-scale experimental robot clusters, the company provides innovative technologies, services, and products for global industries such as biomedicine, chemicals, new energy, and new materials.